Anti-PLA2R1 Antibodies Containing Sera Induce In Vitro Cytotoxicity Mediated by Complement Activation

Table 3

Factors associated with remission at month 6 in patients treated with rituximab ().

	Remission at month 6	No remission at month 6	value
Age			0.12
Sex ratio (M/F)	2.3	11	0.21
Proteinuria at diagnosis (g/g)	4.9 (3.3; 10.4)	7.2 (4.6; 11.4)	0.08
Anti-PLA2R1 total IgG (RU/ml) at diagnosis	73.0 (39.5; 209.0)	185.0 (147.0; 893.0)	0.01
Anti-PLA2R1 IgG4 (RU/ml) at diagnosis	885.0 (220.5; 2669.0)	2824.0 (420.5; 5538.0)	0.12
Spreaders at diagnosis	11/25 (44%)	10/12 (83%)	0.04
Complement-mediated	5/25 (20%)	7/12 (58%)	0.03

Data are presented as (%) or or as median with interquartile range. Remission is defined as  g/g and serum  g/l. Spreaders are defined by samples with anti-CysR reactivity with additional anti-CTLD1 and/or anti-CTLD7 activities additional to anti-CysR reactivity.